First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with…
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S.…
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting…
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian…
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate…
– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response…
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of…
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of…
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma ForumSOUTH SAN FRANCISCO, Calif., March…